% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Dec 10, 2013 1:37 PM Flag

    Clinical Advances 2013: ASCO Annual Report

    posted ahead of print 12/10/13 as an early release to the JCO. Cabo gets mentioned several times in this 33 page document. Good read...
    " The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) directly funded two of the research studies featured in this year’s report: first, preclinical research on how a new targeted therapy called AGI-5198 inhibits growth of cancerous cells in glioma, and second, a clinical trial showing that a new kinase inhibitor, cabozantinib, results in an antitumor effect and reduction of circulating tumor cells in advanced prostate cancer."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $$$$
      "Patients with RET-positive tumors were enrolled onto a phase II clinical trial of cabozantinib, and those with ROS1-positive tumors were enrolled onto a phase I study of crizotinib, which blocks ROS1, ALK, and MET proteins. Cabozantinib blocks several tyrosine kinases, including RET, and is approved for the treatment of medullary thyroid cancer. Two of five patients treated with cabozantinib and one of five treated with crizotinib experienced some tumor shrinkage. Further evidence of the benefit of crizotinib in patients with ROS1-positive lung cancer was presented at the 2013 ASCO annual meeting, showing substantial tumor shrinkage in 14 (56%) of 25 patients.62
      Taken together, the results of the studies confirm that RET and ROS1 fusions occur more frequently among patients with no other known mutations in lung cancer genes than in the general population of patients with lung cancer. These findings suggest that patients whose tumors do not harbor mutations in other lung cancer genes should be screened for ROS1 and RET gene fusions..." (and treated for those mutations)

11.15+0.11(+1.00%)Aug 31 4:00 PMEDT